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Background: Lp(a), a large glycoprotein (apo[a]) attached to an apoB containing particle, has gained attention as a heritable CAD risk factor 
and a novel therapeutic target. Two variants in LPA have been reported to influence Lp(a) levels, explain a large percentage of Lp(a) variability, and 
increase CAD risk. We prospectively tested these variants for their association with Lp(a) levels and their predictive ability for CAD.
Methods: Participants (n=1401) in the Intermountain Heart Collaborative Study registry who had Lp(a) cholesterol (C) levels determined at 
the time of coronary angiography (Atherotech, Birmingham, AL; normal, ≤ 10 mg/dL) were genotyped for rs3798220 and rs1045587 in the LPA 
gene. Genetic variants were detected by Taqman real-time PCR. Chi-square and linear and logistic regression tests were used as appropriate for 
associations among genotypes, Lp(a), and angiographic CAD.
Results: Age averaged 63 years; 65% were men; severe CAD was present in 55%, mild CAD in 12%, and no CAD in 33%. Minor allele frequencies 
were rs3798220=0.023, rs1045587=0.090. In multivariable modeling, initially forcing in the 2 SNPs and 9 clinical variables, only rs1045587 (odds 
ratio [OR]=2.33, CI 1.67-3.33, p=1.75 x 10-9) and rs3798220 (OR=1.99, CI 0.99-4.00, p=0.065) contributed to prediction of elevated Lp(a). Lp(a) 
weakly predicted CAD (OR=1.042 per mg/dL, CI 1.00-1.087,p=0.047). Rs1045587 more strongly predicted CAD (OR=1.75; CI 1.22-2.52, p=0.006), 
but the rare rs3798220 variant only trended to be predictive (OR=1.76, CI 0.88-3.52, p=0.12), after adjusting for coronary history and risk factors. 
Further adjustment for Lp(a) resulted in minor attenuation. The combined genotype explained only a small percentage (<4%) of variability in Lp(a)-C 
and angiographic CAD.
Conclusion: We prospectively validated and quantified heritable contributions of rs1045587 and rs3798220 to Lp(a)-C levels and assessed their 
predictive ability for a carefully defined angiographic CAD phenotype. In contrast to an earlier report, the degree of variability in Lp(a)-C and CAD 
predicted by genotype was small, suggesting that LPA genotyping likely will not be useful for clinical CAD risk assessment.
